Acumen Pharmaceuticals Inc (ABOS)
$3.48
+0.07
(+2.05%)▲
Performance
- $3.40$3.57$3.48
2.3%
Downside
Day's Volatility :4.76%
Upside
2.52%
- $1.81$7.62$3.48
47.99%
Downside
52 Weeks Volatility :76.25%
Upside
54.33%
Returns
| Period | Acumen Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 7.57% | 6.5% | 0.0% |
6 Months | 5.25% | 7.1% | 0.0% |
1 Year | -51.97% | 9.8% | 0.0% |
3 Years | -79.42% | 14.2% | -20.2% |
Highlights
Market Capitalization | 194.1M |
Book Value | $4.36 |
Earnings Per Share (EPS) | -1.05 |
Wall Street Target Price | 12.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -16.82% |
Return On Equity TTM | -25.36% |
Revenue TTM | 329.0K |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -32.4M |
EBITDA | -65.7M |
Diluted Eps TTM | -1.05 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.16 |
EPS Estimate Next Year | -1.42 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.27 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 267.82%
Technicals Summary
Sell
Neutral
Buy
Acumen Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Acumen Pharmaceuticals Inc | 57.87% | 5.25% | -51.97% | -79.42% | -81.96% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Acumen Pharmaceuticals Inc | 3.26 | NA | NA | -1.16 | -0.25 | -0.17 | NA | 4.36 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Acumen Pharmaceuticals Inc | Buy | $194.1M | -81.96% | 3.26 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Acumen Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 113.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 265.9%
Institutional Holdings
RA Capital Management, LLC
24.85%Sands Capital Ventures, LLC
5.69%Franklin Resources Inc
5.65%Millennium Management LLC
4.38%Rock Springs Capital Management LP
3.83%FMR Inc
3.48%
Company Information
acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.
Organization | Acumen Pharmaceuticals Inc |
Employees | 51 |
CEO | Mr. Daniel J. O'Connell M.B.A. |
Industry | Healthcare |
